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Endothelial cell-derived
extracellular vesicles impair the
angiogenic response of
coronary artery endothelial cells
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Michael Brown1 , Ruben M. L. Colunga Biancatelli2 ,
John D. Catravas2,3 and Anca D. Dobrian1*
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Cardiovascular disease (CVD) is the most prominent cause of death of adults
in the United States with coronary artery disease being the most common
type of CVD. Following a myocardial event, the coronary endothelium plays
an important role in the recovery of the ischemic myocardium. Specifically,
endothelial cells (EC) must be able to elicit a robust angiogenic response
necessary for tissue revascularization and repair. However, local or distant
cues may prevent effective revascularization. Extracellular vesicles (EV) are
produced by all cells and endothelium is a rich source of EVs that have
access to the main circulation thereby potentially impacting local and
distant tissue function. Systemic inflammation associated with conditions
such as obesity as well as the acute inflammatory response elicited by
a cardiac event can significantly increase the EV release by endothelium
and alter their miRNA, protein or lipid cargo. Our laboratory has previously
shown that EVs released by adipose tissue endothelial cells exposed to
chronic inflammation have angiostatic effects on naïve adipose tissue EC
in vitro. Whether the observed effect is specific to EVs from adipose tissue
endothelium or is a more general feature of the endothelial EVs exposed
to pro-inflammatory cues is currently unclear. The objective of this study
was to investigate the angiostatic effects of EVs produced by EC from the
coronary artery and adipose microvasculature exposed to pro-inflammatory
cytokines (PIC) on naïve coronary artery EC. We have found that EVs from
both EC sources have angiostatic effects on the coronary endothelium. EVs
produced by cells in a pro-inflammatory environment reduced proliferation
and barrier function of EC without impacting cellular senescence. Some of
these functional effects could be attributed to the miRNA cargo of EVs.
Several miRNAs such as miR-451, let-7, or miR-23a impact on multiple
pathways responsible for proliferation, cellular permeability and angiogenesis.
Collectively, our data suggests that EVs may compete with pro-angiogenic
cues in the ischemic myocardium therefore slowing down the repair
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response. Acute treatments with inhibitors that prevent endogenous EV
release immediately after an ischemic event may contribute to better efficacy
of therapeutic approaches using functionalized exogenous EVs or other
pro-angiogenic approaches.
KEYWORDS

exosomes, barrier function, endothelial cells, proliferation, adipose tissue, wound
response, miRNA

Introduction

of angiogenesis dependent or independent of inflammatory
mediators are extracellular vesicles (EVs) (7, 8). EVs are a
heterogeneous population of lipid bilayer encapsulated cargo
that are secreted by virtually all cell types under both
basal and pathological conditions (9). These vesicles contain
cargo including lipids, proteins, microRNAs and other noncoding RNAs which can contribute to the modulation of
biological function in recipient cells. Specifically, ECs are major
contributors to the EV pool in the systemic circulation and the
heterogeneity inherent to endothelium is reflected by their EVs
released in circulation (9). EC-derived EVs can deliver cargo
such as proteins, mRNA, and miRNA that may modulate the
proliferation, migration, and angiogenic capabilities of recipient
endothelial cells (8, 10, 11). Also, EVs from mesenchymal
stem cells released under hypoxic conditions were shown to
support the angiogenic process following myocardial ischemia
(12). Recent studies also emphasized the beneficial role of EVs
released after remote ischemic conditioning for myocardial
protection and angiogenesis (13). Despite evidence for the
beneficial roles of EVs from various cellular sources on cardiac
remodeling and repair in pre-clinical models, these were not
yet translated into effective therapies for patients with MI.
A thorough understanding of the complex interplay between
EVs from various sources and the local microenvironment in
the heart are therefore of prime importance to ensure efficacy
and safety of promising therapeutic approaches using EVs. Some
evidence shows that EVs can also reduce angiogenesis in vitro
and in vivo (8). Direct and indirect evidence indicates that EVs
from adipose and other distant tissues can effectively reach the
cardiac coronary circulation and induce functional effects in
the endothelium and cardiomyocytes (13–15). Published data
from our laboratory showed that EVs released by human adipose
tissue ECs exposed to chronic inflammation have angiostatic
effects on naïve, proliferating ECs from adipose tissue in vitro
(16). This paracrine effect can reduce vascular remodeling in
an expanding adipose tissue resulting in local inflammation
and insulin resistance. Angiostatic EVs could also impact on
coronary circulation and prevent effective post-ischemic revascularization. Also, it is currently unclear whether this effect
is specific to EVs from adipose tissue endothelium or is also
a feature of coronary EC-EVs exposed to pro-inflammatory

Cardiovascular disease (CVD) is the most prominent
cause of death of adults in the United States, killing
approximately 655,000 Americans each year (1). Coronary
artery disease, the most common type of CVD, can lead to
myocardial infarction, defined by myocardial cell death due
to prolonged ischemia (2). The extent of ischemia-induced
damage to the myocardium greatly depends on the duration
of ischemia and efficient tissue repair. Thus, a timely and
robust repair response is imperative for maintaining normal
organ function. Specifically, successful reperfusion paired with
de novo formation of blood vessels after a myocardial infarction
is necessary not only to repair the ischemic myocardium but
also to prevent heart failure by promoting left ventricular
remodeling (3). The coronary endothelium plays an important
role in this repair response following an ischemic event. Under
physiological conditions, ECs are quiescent and thus contribute
to the maintenance of blood flow and barrier function
while counteracting thrombosis and vascular inflammation
(4). However, following a myocardial event, ECs become
activated, increasing vascular permeability and angiogenesis.
Following an initial inflammatory response, a reparative phase
ensues resulting in attenuation of inflammation, fibroblast
proliferation, and neovascularization via angiogenesis (3, 5).
Angiogenesis is a tightly regulated process controlled via
multiple cues such as hypoxia, vascular endothelial growth
factor (VEGFA), nitric oxide (NO), or other local mediators
(6). When exposed to angiogenic signals, quiescent ECs
become activated, loosening their tight junctions, and thus
allowing extravasation of plasma proteins forming a provisional
matrix. This matrix allows specialized ECs, termed tip
cells, to migrate initiating the formation of a new sprout.
Furthermore, neighboring EC, stalk cells, proliferate to further
elongate the sprout. Individual elongated sprouts will then
coalesce, forming a lumen and new vascular networks (6).
Therefore, cell migration, proliferation and increased vascular
permeability have a concerted contribution to successful
angiogenic responses. Despite this well-regulated process,
several paracrine or endocrine factors may impact on EC
angiogenic response. One emerging player in the modulation
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3, Capture Time Length: 10-s, Temperature: 25◦ C). Expression
of extracellular vesicle tetraspanin expression was determined
using the ExoView R100 platform (NanoView Biosciences,
Brighton, MA, United States).

cues. The objective of this study was to investigate the
angiogenic effects of EVs produced by adipose microvasculature
(heterologous) or coronary artery (autologous) ECs exposed
to pro-inflammatory cytokines (PIC) on naïve coronary artery
ECs. Specifically, we measured EVs effects on functional aspects
that support angiogenesis, such as barrier function, migration
and proliferation. We also determined the potential functional
miRNA cargo in the EVs that may provide mechanistic
hypotheses to the observed functional effects.

Extracellular vesicles labeling
The lipophilic dye Vybrant DiD (Thermo Fisher Scientific,
catalog no. V22887) was used to label autologous or adipose
endothelial cell-derived EVs. Vybrant DiD dye was diluted
1:200 with PBS containing EVs and incubated for 20 min at
37◦ C. Unbound dye in the vesicle preparation was removed by
ultracentrifugation at 100,000 × g for 90 min. The labeled pellet
was then washed and resuspended in filtered PBS and spun again
at 100,000 × g. The final labeled EV pellet was kept in filtered
PBS, at 4◦ C for 24 h.

Materials and methods
Endothelial cell culture
Human coronary artery endothelial cells (HCAEC) were
cultured using either complete EGM-2MV Bullet Kit media
(Lonza, catalog no. CC-3202) or MesoEndo Cell Growth
Medium (Cell Application, catalog no. 212-500) in a 37◦ C, 5%
CO2 incubator. Human adipose microvascular endothelial cells
(HAMVEC) were cultured on fibronectin-coated plates using
complete Endothelial Cell Media (ScienCell catalog no. 1001)
in a 37◦ C, 5% CO2 incubator. Experiments were conducted
between passages 5–8 for both cell types. Endothelial cells were
treated with pro-inflammatory cytokines, 5 ng/mL of TGF-β,
IFN-γ, and TNF-α (designated as PIC) for 6 days, with a media
change and addition of fresh cytokines after 3 days, as previously
described (17). All culture conditions were performed in the
above respective media. The same media was used for all the
functional assays. Please note that media contained 2% FBS and
growth factors including VEGF, for optimal cell growth and as
recommended by manufacturer.

Uptake of extracellular vesicles using
imaging flow cytometry
Human coronary artery endothelial cell (100,000 cells) were
seeded onto a six-well plate and grown until approximately
70% confluency. Cells were then incubated for 24 h with
50,000 EVs/cell of DiD-labeled EV-C or EV-PIC derived from
autologous or heterologous ECs. The media was removed, and
wells were washed with PBS. Cells were then treated with
trypsin, pipetted through cell strainers into Eppendorf tubes,
and pelleted at 220 × g for 5 min. The supernatant was
discarded, and cell pellets were resuspended in 1 mL of PEB
Buffer (1X PBS, 0.5% BSA, 2 mM EDTA, pH 7.4) followed by
centrifugation at 220 × g for 5 min. Cells were then fixed on
ice in 2% formaldehyde/PBS for 20 min and protected from
light. After fixation, the cells were pelleted at 220 × g for
5 min, resuspended in 1:1000 DAPI solution, and incubated
for 5 min. Cells were then pelleted at 220 × g for 5 min,
supernatant was removed, and cells were resuspended in 30–
40 µL 2% Fetal Bovine Serum/PBS (FBS, ScienCell cat no.
#050). Cells were analyzed on an AMNIS ImageStream Mark
II instrument and acquisition, and analyses were completed
using Ideas 6.2 software. Specifically, the Ideas internalization
wizard was utilized to determine the percentage of cells in each
population that internalized EVs. To do so, the wizard uses a
mask feature to calculate the intensity of DiD-stained EVs found
within the masks placed over the brightfield image cells.

Extracellular vesicles isolation and
characterization
The cell culture media from untreated or PIC-treated
HCAEC and HAMVEC seeded in T-150 flasks was collected
after 6 days of treatment. The conditioned media was
centrifuged at 500 × g for 10 min to remove dead cells,
and the supernatant was collected and further centrifuged at
9,100 × g for 40 min to remove small cellular debris and larger
particulates. The supernatant was retained, and vesicles were
isolated by subsequent ultracentrifugation at 100,000 × g for
90 min. The supernatant was removed, and pelleted vesicles
were resuspended in PBS and washed using an additional
ultracentrifugation at 100,000 × g for 90 min. The supernatant
was discarded, and the pellet containing purified EVs was
resuspended in 500 µL of PBS. To determine concentration
and size distribution, EVs were diluted 1:100 in PBS and
nanoparticle tracking analysis was performed using NanoSight
300 (Camera Level: 13–15, Screen Gain: 1, Capture Number:
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In vitro tube formation
Human coronary artery endothelial cell were grown on sixwell plates until approximately 70% confluency was reached.
Cells were then incubated with either autologous or adipose
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ECIS model 1600R ζθ instrument (Applied Biophysics).
Approximately 50,000–75,000 cells were seeded in each well,
let grow overnight and experiments were conducted when a
stable resistance was achieved above 800 , which is indicative
of a confluent monolayer (18). Cells were then exposed to
autologous or heterologous EVs isolated from conditioned
culture media of human coronary EC (HCA) or human adipose
tissue EC (HAM), cultured in presence or absence of proinflammatory cytokines (EV-C or EV-PIC). For wounding
assays, cells were pre-treated with different types of EVs and
then pulsed with 3000 µAmps for 30 s. A number of 3–5
EV preparations for each experimental condition were used.
Resistance values were collected and normalized to each well’s
value at t = 0. Data are represented as mean values (±SEM).
Results were considered significant when p < 0.05 with two-way
ANOVA and Bonferroni’s post hoc test. Also, time-dependent
resistivity was plotted for 3 discrete time points and the area
under the curve (AUC) of the normalized TER values was
computed and compared using the non-parametric Mann–
Whitney test.

EC-derived EV-C or EV-PIC for 24 h. Prior to seeding on
Matrigel, cells were >90% confluent, approaching quiescence.
Growth factor reduced Matrigel (Corning, catalog no. 356231)
was thawed overnight on ice at 4◦ C. The Matrigel was then
diluted 1:1 with EGM-2MV Bullet Kit Media or MesoEndo
Cell Growth Medium, and 150 µL of the diluted Matrigel was
aliquoted into wells of a 48-well plate. Plates were then incubated
at 37◦ C, 5% CO2 for 35 min to allow the Matrigel to settle.
Following EV treatment, HCAEC were incubated with 1 g/mL
calcein AM in growth media for 30 min at 37◦ C, 5% CO2,
and excess dye was removed by 2 × PBS washes. Following
incubation with calcein AM, cells were treated with trypsin,
and each well was seeded with 35,000 HCAEC and allowed to
grow in a 37◦ C, 5% CO2 incubator for 6 h. Cells were then
imaged using an Olympus 72 fluorescent microscope using
40× magnification. Average mesh formation was assessed using
ImageJ Angiogenesis Analyzer software.

Endothelial cell proliferation
50,000 HCAEC were seeded into four-well chambered
slides and grown until approximately 70% confluent. Cells
were incubated with EV-C or EV-PIC from autologous or
adipose ECs for 24 h. Following vesicle treatment, cells were
incubated with 10 µM BrdU (Abcam, catalog no. ab142567)
in growth media for 16–18 h. BrdU labeling solution was
removed from the wells, and cells were washed 3× with PBS.
The cells were then fixed with 2% paraformaldehyde/PBS at
room temperature for 30 min. Wells were washed 3× with PBS,
and permeabilized with 0.1% Triton X-100 for 30 min. Wells
were then washed 3× with PBS, and cells were hydrolyzed with
2M hydrochloric acid for 20 min at 37◦ C. Hydrochloric acid
was removed and sodium tetraborate was added for 30 min
at room temperature. Wells were washed 3× with PBS, and
cells were blocked with 10% Normal Goat Serum (NGS; Vector
Labs, cat#: S-1000) for 1 h. After additional three washes with
PBS, the cells were incubated with anti-BrdU Alexa Fluor
488 antibody (Santa Cruz Biotechnology, catalog no. SC-32323
AF488) and 5 µg/mL DAPI prepared in 10% NGS. Wells were
washed 3× with PBS, and coverslipped with Fluoromount-G.
Three images/well in duplicate wells were captured and further
analyzed. Representative images were taken at 200× with an
Olympus BX50 fluorescence microscope.

Nanostring miRNA analysis
Human coronary artery endothelial cell and HAMVEC
were grown in T-150 flasks until they reached approximately
70% confluency. Cells were then treated with control or PIC
media. Following 6 days of treatment, conditioned media was
harvested, and EVs were isolated, as previously described (17).
Total RNA from vesicles was extracted using Norgen Single
Cell RNA Purification Kit (Biotek Corporation, catalog no.
51800). Extracellular vesicle RNA were analyzed for expression
of 800 miRNAs using Human v3 miRNA panel (Nanostring
Technologies, Seattle, WA, United States). Nanostring nCounter
software was used to normalize the results. Experimentally
validated miRNA targets and downstream pathways were
identified using Qiagen ingenuity pathway analysis (IPA)
miRNA target filter analysis tool in conjunction with PubMed
literature review.

Senescence assay
100,000 cells were seeded into six-well plates and allowed to
grow to 50–60% confluency, and cells were treated EV-C or EVPIC overnight. Cells were stained for β-galactosidase according
to the Senescence β-Galactosidase Staining Kit (Cell Signaling
Technology, cat#:9860). Briefly, the endothelial growth media
was removed from the plate and washed once with PBS. Wells
were incubated with 1X fixative for 15-min, and the plate was
washed twice with PBS. 1.0 mL of β-galactosidase staining
solution (pH 6) was added to each well, and the plate was
covered and wrapped in parafilm. The plate was stored for

Endothelial barrier function and
wounding
Human coronary artery endothelial cells (HCAEC) were
seeded on 96-well gold electrode arrays (96W10idf), and
endothelial barrier integrity was assessed by Electric CellSubstrate Impedance Sensing (ECIS) technique, using an
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We further confirmed the presence of the typical tetraspanin
EV markers CD63, CD81, and CD9 using the ExoView
R100 platform and the proprietary antibody array chips
(Figures 1C,D). Specifically, EVs were captured on chips
containing CD63 antibodies, incubated with a fluorescent
antibody cocktail and imaged. While all EV subtypes displayed
various levels of expression of the three small EV markers,
there was a clear shift in their tetraspanin profile following
PIC treatment (Figure 1C). In the autologous EV population
from PIC conditioned media, 62% of the EVs expressed CD63
compared to only 25% of the control EV population. The
heterologous (adipose-derived) EV population from EC treated
with PIC showed CD63 positivity for ∼95% of the EVs
compared to 25% for the EVs from control cells (Figure 1D).
These results show that the tetraspanin profile of EC-derived
EVs may change in response to proinflammatory cytokines,
which may play a role in EV uptake and by target cells and
possibly their functional outcome.
Next, we compared the cellular internalization of autologous
(HCA EV-C and HCA EV-PIC) and heterologous (HAM
EV-C and HAM EV-PIC) EVs by HCAEC at 70–80%
confluency, which mimics a low proliferative state for
ECs. The internalization of fluorescently labeled EVs was
determined by imaging flow cytometry after incubation
of coronary EC with 50,000 EVs/cell for 24 h (Figure 2).
Titration experiments were performed to determine the
kinetics of internalization and found a saturable effect
reached for 50,000 EVs/cell. Comparison of percent
cells that show a positive signal for internalization for
different EV populations showed that there were no
differences in the numbers of cells that internalized the
EVs (Figure 2B). This result indicates that the cells have a
similar internalization capacity regardless whether the EVs
originate from autologous or heterologous sources and, the
pro-inflammatory environment has no significant effects on EV
internalization.

18-h in a non-CO2 incubator. Cells were then washed with
PBS and stained with DAPI (1:1000 for 5 min) and washed
once more with PBS. β-galactosidase staining was recorded
using bright-field microscopy and DAPI staining was recorded
using fluorescent microscopy. Both images were taken using
an Olympus IX 73 microscope. Senescence was reported as the
percent beta-galactosidase positive cells relative to total number
of cells as detected by DAPI staining.

Statistical analysis
Statistical analysis was performed using GraphPad Prism
Software v7.03 (GraphPad Software). Data is expressed as
the mean ± standard deviation. Normality assumptions were
verified using Shapiro–Wilk tests. If data passed assumptions,
student’s t-test was performed for comparisons of two groups,
and ANOVA was performed for comparisons of three or
more groups. A Tukey’s HSD test was performed for post hoc
analysis of groups when utilizing ANOVA. If data failed either
assumption, non-parametric tests, such as Wilcoxon Rank,
Kruskal–Wallis, and Mann–Whitney tests were conducted to
determine significance. The null hypothesis was rejected for
p-value < 0.05.

Results
Endothelial cells release
heterogeneous extracellular vesicles
that are internalized by human
coronary artery endothelial cell
Coronary artery and adipose microvascular ECs were
treated for 6 days with a combination of TNF-α, IFN-γ, and
TGF-β (PIC) (5 ng/mL each). In our previous study, we used
this combination as it was shown to be increased in adipose
tissue of obese humans (19, 20). Furthermore, this combination
of cytokines has been shown to also be increased in CVD and
ischemic injuries, and was used at similar concentrations in
various in vitro studies involving coronary artery ECs (21–24).
EVs were collected from conditioned media of control (EV-C)
or PIC (EV-PIC) treated ECs and separated using differential
ultracentrifugation. We found that both coronary artery and
adipose microvascular ECs treated with PIC release ∼2–3-fold
more EVs compared to untreated, control ECs (Figure 1A).
EVs from control ECs have similar size distributions with an
average peak around 140 nm, while ECs treated with PIC are
on average slightly larger, with an average peak between 150 and
158 nm (Figure 1A). EV size was confirmed by negative staining
electron microscopy and their morphology showed the typical
cup-shaped feature (Figure 1B).

Frontiers in Cardiovascular Medicine

Endothelial cell-derived vesicles have
angiostatic effects on human coronary
artery endothelial cell and reduced
their proliferation
To determine the angiogenic potential of the EVs on
coronary endothelium, we performed in vitro tube formation
assays in the presence of VEGFA. Coronary cells require VEGF
to proliferate in vitro and absence of VEGF from media
completely prevents tube formation. Following 24-h exposure
to 50,000 EVs/cell from either autologous or heterologous
sources in absence or presence of PIC, mesh formation was
measured and compared with control coronary cells without
EV treatment (Figure 3). Mesh formation is a measure of
coordinated development of tips and branches, and it illustrates
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FIGURE 1

Production and characterization of autologous (human coronary artery – HCAEC) and heterologous (human adipose tissue – HAMVEC)
endothelial cell EVs in response to pro-inflammatory cytokines (PIC) treatment. (A) Nanoparticle tracker analysis found similar size distribution
of EVs isolated from untreated cells (EV-C) and from PIC-treated cells (EV-PIC) for both autologous and heterologous EVs. Please note that PIC
treatment resulted in a 2–3-fold increase in EV numbers/cell compared to untreated controls for both populations of EVs. (B) Representative
micrographs of negative staining electron microscopy for EV-C and EV-PIC from HCAEC and HAMVEC sources. EM confirms the EV size range
calculated by nanoparticle tracking analysis in both preparations and illustrates the typical donut-shaped morphology of the EVs from both
cellular sources. (C) Fluorescent images of ExoView chips of EVs from HAMVEC (left) and HCAEC (right) showing expression of the EV marker
CD63. Please note that EVs from both cellular sources that were treated with PIC showed a strong increase in CD63 expression.
(D) Quantification of relative fluorescence for the tetraspanins CD63, CD9, and CD81 using the ExoView technology shows the different relative
expression of each EV population. Similar tetraspanin relative expression was found for EVs from control HAMVEC and HCAEC and increased
expression of CD63 was found on EVs from both type of endothelial cells treated with PIC.

for angiogenesis, such as proliferation, barrier function, and
cell migration to identify potential mechanisms underlying the
angiostatic effect.
Since mesh formation was significantly reduced by EVs,
we measured the impact of the latter on the proliferative
capacity of coronary endothelial cell measured by BrdU
incorporation (Figure 4). HCAEC at 60–70% confluency were
treated with 50,000 EVs/cell for 24 h prior to measurement
of proliferation. Heterologous EVs (HAM EV) significantly
reduced proliferation compared to untreated controls, on
average by 28 and 63% in the absence or presence of PIC
treatment of the parent cells, respectively (Figures 4A,B).
Autologous EVs produced by cells treated with PIC (HCA
EV-PIC) significantly decreased EC proliferation by ∼50%
compared to controls, while HCA EV-C produced by cells in
absence of inflammatory cytokines had no significant effect
on coronary EC proliferation, although they displayed a trend
toward decreased proliferation (Figures 4A,B). Based on this
data, it appears that heterologous EVs may lead to a decreased
mesh formation by HCAEC, at least in part, due to slowing
down the rate of EC proliferation. This scenario is also
supported by data from HCAEC exposure to autologous EVs

an angiogenic response leading to a primitive network of
EC that forms vascular lumens. We found that in contrast
with control cells, HCAEC treated with EVs show varying
levels of incompleteness of mesh formation that suggests
an imbalance between sprouting, elongation and branching
of the network (Figure 3A). Heterologous EVs (HAM-EV),
regardless of PIC exposure of the parental cells, led to a
significant reduction by ∼50% of the mesh compared to
control, untreated HCAECs (Figure 3C). Autologous EVs
(HCA EV) had a more dramatic effect leading to almost
complete abolition of the mesh structure and, the effect was
equally potent regardless exposure of parental cells to PIC
(∼75% reduction in mesh formation compared to untreated
control) (Figure 3D). This effect was comparable with the
one resulting from direct addition to the media of the
PIC, in the absence of EVs (Figure 3B). Since EVs were
added to the HCAEC prior to their seeding in matrigel it is
unlikely that the EVs directly interfered with VEGF binding
to its receptor. However, other mechanisms that involve postreceptor signaling may have direct or indirect impact on
functions such as cell proliferation or migration. Therefore,
this data led us to assess other functional parameters required
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B

A

Vesicle Internalization by
Coronary Artery Endothelial Cells
100

FIGURE 2

EV uptake by human coronary endothelial cells (HCAEC) is independent of EV source. (A) HCAEC were incubated with DiD labeled HCAEC or
HAMVEC EV C or EV PIC for 24 h prior to imaging flow cytometry. The number of cells that showed a detectable positive signal was determined
using the IDEAS software internalization wizard. (B) Uptake was calculated as percentage of cells that were positive for the DiD fluorescence
following the background subtraction of control cells incubated with EV-free dye. Uptake was similar for all the EV populations (n = 3 individual
preparations). Non-parametric ANOVA found a p-value = 0.649. HAMVEC, human adipose tissue microvascular endothelial cells; EV C,
extracellular vesicles isolated from control cells; EV PIC, extracellular vesicles isolated from PIC-treated cells.

measured over 24 h (Figure 5). Pre-treatment with autologous
EVs from control unstimulated cells (HAM EV-C) led to a
rapid and full recovery of the cell monolayer post-wounding
(Figures 5A,B). At the end of the 24-h measurements the cells
pre-treated with EVs from cytokine stimulated HCAEC (HCA
EV-PIC) had significantly lower normalized transendothelial
resistance than the HAM EV-C treated cells, indicating a
significant reduction in wound recovery due to reduced
migration (Figures 5A,B). Interestingly, control cells in the
absence of EV treatment did not fully recover from wounding,
compared to a no wound control. This suggests, that autologous
EVs may support endothelial repair following injury. Pretreatment with heterologous EVs (HAM EV-C and HAM EVPIC) did not change the wound recovery compared to control
non-treated ECs. None of the cell monolayers post-wounding
fully restored their integrity (Figures 5C,D). The integrated
wound response over 24 h, expressed as the area under curve
(AUC) of the normalized TER further indicates the unique
restorative response of HCAEC pre-treated with autologous
EVs from control, unstimulated cells (Figure 5E). However, the
angiostatic effect of EVs on the coronary endothelium cannot be
directly attributed to differences in EC migration, at least under
the methodological approaches used in these experiments.
Initiation of angiogenesis is associated with an increase in
EC monolayer permeability and the loosening of endothelial
junctions. Therefore, we measured endothelial barrier function
in response to EV treatment. Under basal conditions, the
vascular endothelium forms a semi-permeable barrier that
controls the transport and passage of molecules. However,

from PIC treated cells, but not from cells in absence of an
inflammation. Since reduced rates of proliferation may be due
to an increase in the number of senescent cells within the EC
population, we also measured the effect of EVs on HCAEC
senescence. We have found that, regardless of their cellular
source and presence of PIC, EV did not have an effect on the
percent of senescent cells, compared to untreated controls, as
measured by a b-galactosidase assay (Supplementary Figure 1).

Endothelial cell-derived extracellular
vesicles modulated human coronary
artery endothelial cell response to
wounding and barrier function
The reduced potential of HCAEC exposed to EVs to
form a tubular network in vitro can be caused by impaired
migration of EC. It is recognized that the ability of tip cells
to migrate toward VEGF gradients is key for the initiation
of angiogenic sprouts in vivo. We used an indirect measure
of migratory function of HCAEC based on their capability
to restore the monolayer integrity in response to wounding.
HCAEC were seeded on a 96 wells 10idf array and connected
to ECIS 1600 R (zeta-theta) instrumentation until they reached
confluency. Autologous and heterologous EVs, obtained from
unstimulated or stimulated (PIC-treated) cells, were added to
HCAEC at a concentration of 50,000 EVs/cell and after 48 h
an electric pulse of 3000 µAmps was applied for 30 s in 10
discrete areas of the monolayer. Recovery from wound was
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FIGURE 3

Extracellular vesicles (EV) from control and pro-inflammatory cytokines (PIC) treated endothelial cells reduce in vitro tube formation.
(A) Coronary artery endothelial cells were incubated for 24 h with EV-free media containing VEGF, PIC + VEGF media, or EV from control or
PIC-treated HAMVEC (HAM EV-C or HAM EV-PIC) or HCAEC (HCA EV-C or HCA EV-PIC) in presence of VEGF. After treatment, cells were
labeled with calcein, seeded in growth factor reduced matrigel coated plates and incubated for 6 h before imaging. Representative micrographs
show reduced formation of complete mesh when treated with EVs from all cellular sources; Magnification 40× (Scale bar = 200 µm). (B–D)
Quantitative analysis of tube formation using the ImageJ software. Data is expressed as percent of mesh reduction relative to control (set at
100%) (n = 5). Statistical analysis was done using the Mann–Whitney non-parametric test. The null hypothesis was rejected for a p < 0.05.
*p < 0.05; **p < 0.01.

chronic inflammation and extracellular vesicles have both been
shown to contribute to vascular endothelial barrier dysfunction
(4, 25). Autologous EVs from PIC treated cells (HCA EV-PIC)

from PIC stimulated cells only, suggesting a sustained longterm response (Figure 6E). In addition to reduced proliferation,
reduced barrier function may be an independent contributor to
angiostatic effects of autologous EVs from PIC stimulated cells.

provoked a decrease in barrier function, indicating increased
permeability of the cell monolayer (Figures 6A,B). This effect
became significant 20 h after EV addition and was maintained
for the following 10 h (Figure 6B). The effect was unique to
the autologous HCA EV-PIC, as EVs from control autologous
cells (HCA EV-C) did not elicit any changes in barrier function
over 30 h of EV exposure, compared to untreated controls
(Figures 6A,B). Exposure to heterologous EVs from cells treated
with PIC (HAM EV-PIC) caused a transient decrease in barrier
function, starting as early as 5 h after exposure to EVs that
recovered after 15 h. Heterologous EVs from untreated cells
(HAM EV-C) did not significantly change the transendothelial
resistance throughout the experiment (Figures 6C,D). The
integrated normalized TER over 30 h, calculated as the AUC,
showed a significant decrease in response to autologous EVs
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miRNA cargo composition in control
and pro-inflammatory
cytokines-treated endothelial cell
extracellular vesicles
Many of the functional effects of EVs on recipient cells are
attributed to their miRNA cargo. We employed an unbiased
analysis of the miRNA cargo of EVs using an 800 miRNA
panel of the Nanostring platform. A number of 18 miRNA were
detectable in the EVs, with 8 miRNA shared by EVs produced by
HCAEC and HAMCEV cells (Figure 7A). HCAEC had 2 unique
miRNAs – miR-346 and miR-150, while HAMVEC had 8 unique
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FIGURE 4

EVs isolated from both PIC treated HAMVEC (heterologous) and HCAEC (autologous) conditioned media decrease HCAEC proliferation.
(A) Representative micrograph of control cells. Cell nuclei are stained with DAPI (blue). Nuclei of the proliferating cells are labeled by a FITCBrdU antibody (green). Overlapping images of the same field show both proliferating cells (light blue nuclei) and non-proliferating cells (dark
blue, DAPI only). Magnification is 200×. (B) Quantitative analysis of HCAEC proliferation expressed as percent cells showing BrdU incorporation
of total cells. Data is expressed as percentage of proliferation for EV-treated cells relative to untreated controls (set at 100%). Statistical analysis
was performed using the Mann–Whitney non-parametric test (**p = 0.0059; *p = 0.0459).

perfusion of the myocardium. Under- or over-perfusion may
both have pathological effects due to inadequate levels of
oxygen and nutrients. Importantly, partial or total occlusion
of coronaries leads to significant ischemic damage to the heart
that can result in pathologic remodeling or death. Timely reperfusion via collateral re-vascularization and angiogenesis are
key to restore cardiac function and physiologic remodeling of
the myocardium. Current therapeutic approaches have limited
success and are particularly challenging in aging populations
and in individuals with co-morbidities such as obesity and type
2 diabetes. A promising contemporary approach involves stem
cell therapy as a mean to repair the myocardium. However,
cellular therapies that involve heterologous cells are challenging
due to immune rejection and autologous cells may have
limited therapeutic benefits due to reduced potency in elderly
individuals or patients with obesity, or existing cardio-metabolic
pathologies. Extracellular vesicles produced by stem cells are a
more appealing alternative, as they can be generated in large
amounts in vitro from stem cells of healthy individuals and
are largely non-immunogenic (28). Some success has been
reported in various pre-clinical models, but the variability in
the response due to local and systemic microenvironment of
the recipient remains a challenge (28). Therefore, amongst other
variables, understanding better the complex interplay between

miRNAs (Figure 7A). Since both autologous and heterologous
EVs had angiostatic effects, IPA miRNA target filter tool was
used to identify experimentally validated target genes of the
shared miRNA, to identify functional miRNA cargo candidates
(Table 1). Eight miRNA were identified in both HCAEC
and HAMVEC EV C and EV PIC, let-7, miR-302, miR-548,
miR-126, miR-23a, miR-451, miR-3144, and miR-4454 + 7975
(Figure 7A). These miRNAs were segregated based on their
predicted functional impact on angiogenesis, proliferation and
barrier function (Figure 7B). Six of the eight miRNA had
predicted effects on angiogenesis (let-7, miR-302, miR-548, miR126, miR-23a, and miR-451), four on proliferation (let-7, miR302, miR-126, and miR-23a) and 3 on barrier function (let-7,
miR-302, and miR-126). The latter had predicted effects on all
the functional categories tested (Figure 7B).

Discussion
Endothelium is a major contributor to the maintenance
of vascular homeostasis and a hub that coordinates responses
to injury and repair in various vascular pathologies through
inherent plasticity (9, 26, 27). Coronary endothelium is of
prime importance for the maintenance of adequate vascular
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FIGURE 5

Pretreatment with autologous and heterologous EVs modulates HCAEC response to wounding. Following 24 h of treatment with different EV
preparations, the cell monolayer was disrupted by the application of an electric pulse of 3000 µAmps for 30 s. A number of 3–5 EV preparations
were used in triplicates for each experimental condition. (A,B) Time-dependent recording of normalized TER indicates full recovery of coronary
cells treated with autologous EVs (HCA EV-C) 24 h after wounding. Control cells with no EV treatment and autologous EVs produced by PIC
treated cells (HCA EV-PIC) failed to fully recover 24 h post-wounding. (C,D) All coronary cells following wounding maintained significantly
lower barrier function at 12 h and up to 24 h post-wounding compared to control cells with no wound. (E) Area under the curve (AUC) was
calculated using the normalized TER data from the time of wounding and over the following 24 h. Resistance was recorded continuously at
600 s intervals and normalized to t = 0. Means ± SEM; ∗ p < 0.05; ∗∗ p < 0.01 with 1- or 2-way ANOVA and Bonferroni’s post hoc test (A) and
Mann–Whitney non-parametric test (B,D,E).

inflammatory environment may be more effective to transfer
functional cargo by competing for uptake with EVs from
other sources. However, we found that HCAEC internalized
both autologous and heterologous EVs from control and
PIC-stimulated cells at a similar rate, in a non-competing
setup when ECs were treated with individual and equal
numbers of each of the EVs populations. The exact mechanism
of EV internalization by HCAEC is yet to be confirmed
but likely involves receptor-mediated endocytosis (data not
shown). We also found that autologous and heterologous
EVs displayed the three tetraspanin exosomal markers, CD63,
CD81, and CD9. Interestingly, when HAMVEC and HCAEC
were exposed to pro-inflammatory cytokine treatment, there
was a robust increase in CD63 expressing EVs (Figure 1).
Although not extensively explored, some studies have shown
that tetraspanins may interact with other transmembrane
proteins to promote EV docking and selective tissue- and celldependent uptake (33, 34). ECs express transmembrane protein
such as integrins and ICAMs, commonly found in tetraspaninenriched microdomains (TEMs) that are used for immune cell
adhesion (8, 35). Thus, such molecules could also be utilized
by EVs for cellular targeting. Findings from animal models

endogenous EVs generated by different endothelia and the
exogenous therapeutic EVs, is of prime importance to optimize
such approaches. In this paper, we focused on understanding
the effects of autologous coronary endothelial EVs and adipose
tissue microvascular EVs, produced in physiologic or proinflammatory conditions, on coronary EC function. We selected
these two human endothelial cell types due to relevance
for the myocardial repair of their EVs as contributors from
local microenvironment (coronary EC) as well as distant
sites, such as adipose tissue (adipose microvascular EC); and
representative of normal or obese conditions characterized by
low grade inflammation (with or without PIC stimulation).
We also built on previous data from our lab showing that
EVs from adipose tissue EC in proinflammatory conditions are
angiostatic for autologous naïve cells (17). Under physiologic
conditions, ECs significantly contribute to the EVs in blood
circulation. Several studies have shown that inflammation
effectively increases EV release by ECs (29–32). In line with
our previously published data, we found that endothelial cells
from different vascular beds stimulated with proinflammatory
cytokines released more EVs compared to control cells. By
virtue of their higher numbers, EVs produced by ECs in an
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FIGURE 6

Effect of autologous and heterologous EVs on human coronary artery endothelium barrier function. HCAEC were seeded on 96W10idf array
until confluent, i.e., until stable resistance was achieved (>800 ). Three to five EC preparations were measured in triplicates for each
experimental condition. (A,B) Treatment with autologous EVs from HCAEC exposed to PIC (HCA EV-PIC) significantly reduced barrier function
compared to untreated controls. This effect is time-dependent and becomes significant after 24 h. Autologous EVs from untreated cells (HCA
EV-C) did not have a significant effect on EC barrier function and the integrity of the cell monolayer was maintained throughout the experiment.
(C,D) Heterologous EVs produced by cells in the presence of pro-inflammatory cytokines (HAM EV-PIC) exhibit early and transient reduction in
barrier function at 5 and 15 h. EVs collected from adipose microvascular cells in the absence of cytokine treatment (HAM EV-C) did not have a
significant effect on barrier function. (E) Area under the curve (AUC) was computed using the normalized TER values over a 30-h interval.
Resistance was recorded continuously at 600 s intervals and normalized to t = 0. Means ± SEM; ∗ p < 0.05; ∗∗ p < 0.01; ****p < 0.0001 with
two-way ANOVA for repeated measures and Bonferroni’s post hoc test (A,C); Mann–Whitney non-parametric test (B,D,E).

have shown that EVs from adipose tissue functionally impact
the cardiomyocytes (15) and EVs from EC of peripheral beds
subject to remote ischemia reperfusion have beneficial effects
on cardiac pre-conditioning (13). Such studies provide an
indirect proof that peripheral EVs can successfully reach the
coronary endothelium. Conversely, EV produced by coronary
endothelium can be potent modulators of immunity and
inflammation post-MI and contribute to myocardial functional
restoration via mobilization of neutrophils from spleen, thereby
triggering an “autocrine” effect via an endocrine route (36).
Based on this proven accessibility of EVs between coronary
circulation and peripheral vascular beds, we speculate that our
in vitro data should bear functional significance in vivo, in a
pathologic context.
Effective angiogenesis is key to support an adequate repair
response following a post ischemic myocardial event. In
this study, we assessed the angiogenic potential of HCAEC
following treatment with EVs derived from coronary or
adipose endothelial cells stimulated with proinflammatory
cytokines. We found that regardless of parental cell treatment
and EC source, all EV preparations significantly impaired
in vitro HCAEC tubule formation, a surrogate for angiogenic

Frontiers in Cardiovascular Medicine

potential. Evidence for anti-angiogenic effects of EVs are by
far less commonly reported compared to their pro-angiogenic
effects (7). In the context of ischemic diseases, the effects
of EVs on coronary ECs are reportedly pro-angiogenic and
emphasized as promising therapeutic interventions. However,
such EVs are primarily produced by stem or progenitor cells
from either endogenous or exogenous sources, not by EC
themselves (28). To our knowledge, the effect of autologous
EVs in normal or pro-inflammatory conditions on coronary
EC angiogenesis were not reported. Some of the mechanisms
underlying inhibitory effects of EVs on angiogenesis include
primarily mechanisms of uptake inhibition such as LDL
receptor endocytosis or CD36-independent uptake or induction
of oxidative stress [reviewed in Todorova., et al (7)]. Also,
published data suggested that high concentrations of ECderived EVs can induce apoptosis and impair angiogenesis
in recipient ECs (37–39). Specifically, Ou et al. found
that increased concentrations of EC-derived EV inhibited
angiogenesis by inducing endothelial nitric oxide synthase
(eNOS) dysfunction (39). Our data indicate that all the tested
EV populations are taken up in an indiscriminate fashion by
∼65–70% of the HCAEC that approach confluence (Figure 2).
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Venn diagrams showing miRNA cargo and predicted functional effects of EVs from human coronary artery cells (HCAEC) and human adipose
tissue microvascular endothelial cells (HAMVEC). (A) HCAEC and HAMVEC EV C and EV PIC miRNA cargo was measured using the Nanostring
miRNA array. Three different EV preparations were used for each experimental condition and only the miRNA that were detectable in all three
EV preparations are shown. (B) Predicted gene targets for all the miRNA detected in the different EV populations were obtained using the IPA
miRNA target filter tool and further sorted by the number of their target genes into functional pathways that included angiogenesis,
proliferation, and barrier function. The greatest proportion of miRNA involvement was found to be in angiogenesis, followed by proliferation,
with the fewest miRNA targets involving barrier function.

recipient EC (41). Nevertheless, further studies will be needed
to fully understand the impact of EVs on endothelial cell
proliferation and migration.
Extracellular vesicles are complexly involved in the
regulation of endothelial barrier and increased permeability
during infectious or inflammatory states (25). Indeed, chronic
vascular diseases like atherosclerosis and diabetes display
increased levels of plasma EVs originating from either platelet,
endothelial cells or leukocytes, that promote microvascular
leakage (43, 44). This has been further supported by the fact
that exosome generation blockade by GW4869, and subsequent
inhibition of EVs release, ameliorates systemic inflammation in
mice (45). EVs isolated during inflammatory states showed to
disrupt endothelial homeostasis and impair vasorelaxation and
eNOS production (46).
We investigated if autologous and heterologous EVs,
obtained in either unstimulated or inflammatory conditions,
would influence the permeability of a monolayer of HCAEC
and their response to wounding. Interestingly, autologous EVs,
obtained after incubation with inflammatory cytokines (PIC)
showed a time-dependent decrease in barrier function, not
observed with EVs isolated in basal conditions (Figure 6).
Furthermore, when cells were pretreated with EVs for 24 h and
then wounded, autologous EVs-derived in non-inflammatory
conditions showed to protect HCAEC from injury and
participate in the re-establishment of a proper barrier function.
Heterologous EV were shown to not influence the permeability
of a HCAEC monolayer. Therefore, EVs do not seem to

Therefore, we focused our efforts to identify alternative
mechanisms that can explain EVs inhibitory effects on HCAEC
angiogenesis beyond their mechanism of uptake; specifically,
we assessed proliferation, barrier function, and migratory
response following EC monolayer wounding. Although all
EV preparations reduced EC proliferation, only autologous
EVs from PIC-stimulated cells reduced barrier function.
Furthermore, control autologous EVs appeared to have aid in
the reestablishment of the HCAEC monolayer following wound
induction. Thus, EC-derived EVs impair several parameters
required for mounting a sustainable angiogenic behavior.
Notably, the most consistent and robust effect of EVs across
all preparations was on EC proliferation. This included EVs
from both PIC-treated and control HAMVEC and HCAEC
cultures. Therefore, we propose that reduced proliferation may
be necessary and sufficient for reduced angiogenesis, even
in absence of a pro-inflammatory environment. As discussed
below, some of the shared miRNA cargo support a uniform
anti-proliferative effect of the EVs. In contrast with our
findings, several studies have shown that EC-derived EVs
promote angiogenesis and proliferation in recipient ECs (40–
42). In one such study, EVs released by ECs contained β1
integrin and enzymatically active matrix metalloproteinases;
these EVs were capable of inducing EC invasion and tubule
formation in vitro (40). Furthermore, Lombardo et al. showed
that EC stimulated with Interleukin-3 (IL-3) secreted EVs
that promoted angiogenesis through the transfer of miR126-3p and pSTAT5, and increased ERK1/2 activation in
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Although EVs are believed to participate in endothelial
inflammation, different reports suggest a protective role.
Clinical studies showed indeed that EVs isolated from septic
patients may also protect vascular tone and contractility and
that, EVs-leukocytes conjugates correlate negatively with organ

be angiostatic due to reduction in migration or increase
in permeability of the HCAECs. However, we uncovered a
potential beneficial role of the physiologic autologous EVs
for recovery of injured endothelium and formation of a tight
monolayer barrier.

TABLE 1 miRNA cargo shared by HCAEC and HAMVEC extracellular vesicles and their validated gene targets involved in angiogenesis, proliferation,
and barrier function.

EV miRNA identified

Mean expression values (Counts)
HCAEC

let-7

Genes targeted

HAMVEC

Functional involvement

EV C

EV PIC

EV C

EV PIC

33.51

36.82

31.80

38.31

Angiogenesis

Proliferation

ACP1

LOXL2

ACP1

F2

ADAMTS2

NRAS

ADAMTS2

RHOB

ADGRG1

MTRR

COL1A1

BSG

MYC

COL1A2

CASP3

PDGFA

COL8A1

CCND1

PDGFB

DICER1

CDK6

PRDM1

F2

COL1A1

PTGS2

HMOX1

COL1A2

RAS

ITGB3

COL4A2

RHOB

LOXL2

COL5A1

RHOG

MYC

COL8A1

SPARC

NRAS

DICER1

TGFBR1

PDGFB

F2

TGFBR2

PTGS2

HMGA2

THBS1

RAS

HMOX1

TLR4

SPARC

ITGB3

VIM

KRAS

210.44

379.95

58.50

55.58

TGFBR1
TGFBR2

LAMC1
miR-302

Barrier function

THBS1

ADAM9

LEFTY1

APP

APP

NR4A2

CD44

CCND1

PRKACB

CDKN1A

CD44

RECK

DKK1

CDKN1A

RELA

NR4A2

DKK1

STK4

VEGFA

ESR1

VEGFA

VEGFA

LMNB1
miR-23a

miR-126

32.38

33.51

20.00

31.05

26.33

45.03

21.84

28.45

CXCL12

PLAU

HES1

PTEN

CXCL12
PLAU

IL6R

SMAD3

PTEN

LMNB1

SMAD4

MET

SMAD5

NOTCH1

TNFAIP3

CRKL

VCAM1

SPRED1

IRS1

VEGFA

VEGFA

VEGFA

SPRED1
miR-451

46.36

33.86

38.70

32.95

MIF

miR-548

97.9

83.51

27.68

27.08

ERBB2

miR-3144

122.91

224.37

27.01

28.38

No experimentally validated targets

miR-4454 + miR-7975

30.58

31.05

35.76

26.80

No experimentally validated targets

HCAEC and HAMVEC EV miRNA target genes were identified using the IPA target filter tool and sorted by involvement in angiogenesis, proliferation, and barrier function.
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to inhibit tumor angiogenesis in multiple malignancies (64).
Therefore, miR-126 delivered via EVs could exert a potential
anti-angiogenic effect in the HCAEC via modulation of the
latter pathway. miR-451, another miRNA detected in the EVs
in this study has been found to be elevated in the blood of
patients of coronary heart disease and inhibits proliferation
in HUVECs (65). Inhibition of miR-451 in HUVECs has
been demonstrated to promote tube formation and increase
migration and invasion (66). miR-548 is downregulated in
the pericoronary adipose tissue of coronary artery disease
patients (67). miR-548 downregulated HMGB1 in human
amniotic epithelial cells (68) and activation of HMGB1 in bone
marrow stem cells stimulates proliferation and angiogenesis
(69). Therefore, delivery of miR-548 to recipient HCAEC may
engage the HMGB1 pathways and therefore reduce proliferation
and tube formation, Our results also indicate that all of the
miRNAs that were reported to induce angiogenesis in coronary
endothelium post-ischemia (14) are, in fact, not detectable in
our EV populations and perhaps it is not surprising that the
functional miRNA cargo in our vesicles do not support proangiogenic mechanisms (Figure 7). Future studies are granted
to validate the role of miRNA EVs in coronary angiogenesis and
to identify potential therapeutic targets.
In this study, we showed the angiostatic and antiproliferative effects of EVs from two EC sources in the
absence and presence of inflammation and described their
modulation of barrier function and recovery from wounding of
human coronary endothelial cells. Our findings are important
to consider when therapies with exogenous functionalized
EVs are contemplated for enhancing post-ischemic coronary
angiogenesis. Endogenous EVs from local or peripheral ECs
may compete for uptake and counteract the therapeutic effects
of the exogenous EVs. Therefore, short term treatment with
small EV release inhibitors prior to exogenous EV delivery may
maximize the potency of such therapeutic approaches.

dysfunction and mortality (47, 48). Our data further suggest
a critical role of EVs in barrier regulation and homeostasis.
Indeed, while EVs produced under physiologic conditions may
help recover the tight junctions between endothelial cells,
EVs produced during inflammatory states may exert an effect
on capillaries increasing permeability and favoring diapedesis
and fluid leakage.
Extracellular vesicle cargo, to a certain extent, mirrors the
miRNA-expressed repertoire of the parent cell and can cause
biological changes to recipient cells. miRNAs are small noncoding RNA that play a role in regulating gene expression
post-transcriptionally by repressing the expression of target
mRNA. Several literature reports substantiate that EVs can
deliver miRNAs to recipient cells, thus impacting the gene
expression of the latter. Amongst these physiologic effects, it
has been shown that miRNAs delivered by EVs can impair
angiogenesis (49). Therefore, we interrogated the miRNA cargo
of the autologous and heterologous EVs from control and PICstimulated cells. miRNA target genes included multiple genes
known to mediate angiogenesis including those involved in
classical VEGF signaling, cell cycle, and extracellular matrix.
Extracellular vesicle miRNAs were found to target several
functions relevant to endothelial cell function and angiogenic
potential. Let-7 is integral to endothelial cell homeostasis
(50). The let-7 family is known to have proangiogenic effects
(51), but several instances of angiostatic activity have been
reported. Some of the anti-angiogenic effects of let-7 are due
to anti- proliferative effects. Since reduced proliferation was
the most consistent effect of EVs both from control and proinflammatory cultures of ECs, we speculate that some of EV
miRNA cargo, such as let-7, uniformly expressed by all EVs
in this study, may have a key role via targeting multiple
genes involved in proliferation (Table 1). Expression of let7 has been shown to increase with age in cardiac stemlike cells (CSLC). Following treatment of CSLC with a let7 mimic, their proliferation was significantly reduced (52).
Angiogenesis is repressed by overexpression of let-7 and by
silencing of the let-7 target gene HMGA2 in EC (53). miR-302
is a member of a cluster known to drive numerous functions
critical to cell homeostasis and function including proliferation,
differentiation, and pluripotency (54). MiR-302 has been shown
to inhibit tumor angiogenesis by targeting VEGFA (55), and
MACC1 (56). Circulating miR-302 has been identified as a
potential biomarker for acute heart failure (57). The miR-23
cluster is highly expressed in EC and has been implicated in
processes supporting angiogenesis (58–60). MiR-23 has also
been implicated in atherogenesis, potentially by supporting a
proinflammatory secretome in HCAEC (61) and has been linked
to cardiomyopathy in mice (62). miR-126 has been implicated in
the promotion of angiogenesis, however, numerous additional
functions have also been observed. miR-126 was shown to
downregulate NFκB-mediated PI3K/AKT/mTOR signaling (63)
and PI3K inhibition has been implicated as a therapeutic target
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